Top Markets
Coin of the day
Lumosa Therapeutics Co., Ltd. Lumosa Therapeutics Co., Ltd.

Lumosa Therapeutics Co., Ltd.

6535
Clasificación en acciones #14754
Lumosa Therapeutics Co., Ltd. is a clinical-stage pharmaceutical company,... Lumosa Therapeutics Co., Ltd. is a clinical-stage pharmaceutical company, headquartered in Taiwan, focused on developing innovative therapies for neurological and oncological diseases. Its most advanced product, LT-1001, an injectable analgesic, has completed Phase III clinical trials for the management of severe post-operative pain. The company's pipeline also includes LT3001, currently in Phase II for treating acute ischemic stroke; LT5001, which has finished Phase Ib trials for uremic pruritus; and LT2003, an oncology drug candidate in its preclinical development stage. Founded in 2000, Lumosa Therapeutics maintains its operational base in Taipei.
Precio por acción
$2.35
Capitalización bursátil
$394.12M
Cambio (1 día)
-1.07%
Cambio (1 año)
-64.75%
País
TW
Comercio Lumosa Therapeutics Co., Ltd. (6535)

Categoría

Ganancias de Lumosa Therapeutics Co., Ltd. (6535)
Ganancias en 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Lumosa Therapeutics Co., Ltd., gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, igual a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Lumosa Therapeutics Co., Ltd. desde 2026 hasta 2026
Ganancias al final de cada año
Año Ganancias Cambiar
Not enough data for the provided dates.
Ganancias de empresas similares o competidoras
Empresa Ganancias Diferencia de ganancias País
$5.27B -
US
$1.95B -
NL
$-4.02B -
AU
$-3.09B -
US
- -
CH